
    
      Efficacy of TDF will be evaluated for reductions in serum HBV DNA, changes in liver enzymes,
      and the generation of antibody to the virus. Safety will be assessed by evaluating adverse
      events, laboratory abnormalities, and the development of drug resistance mutations.
    
  